PDF(Pubmed)
Abstract：
Caspases are key players in the apoptotic process and have been found to contribute to the pathogenesis of a variety of diseases, including neurological disorders such as ischemic stroke. This study aimed to investigate the serum levels of Caspase-3 in patients with acute ischemic stroke (AIS) and in control patients without ischemic events. Moreover, we explored any potential associations with the clinical outcomes of AIS. We enrolled 69 consecutive patients with clinical signs and symptoms of AIS in the presence of a negative CT scan who presented themselves at the Clinical Neurological Department from the Emergency Clinical Hospital of Galati within the first 24 h of symptom onset. The control group comprised 68 patients without cerebral ischemic pathologies. A comparison of the two groups showed significantly higher levels of caspase-3 at 24 and 48 h after hospital admission. No significant associations between caspase-3 levels and clinical features of AIS were seen. However, in a subgroup analysis conducted on patients with moderate/severe and severe stroke, lower levels of caspase-3 were associated with early mortality. Caspase-3 levels did not directly correlate with AIS severity or prognosis when considering all AIS patients. In patients with moderate to severe National Institute of Health Stroke Scale (NIHSS) scores, caspase-3 might be a prognostic indicator of early death. Further studies are required to confirm these results and further explore the mechanisms behind these findings.
摘要：
半胱天冬酶是细胞凋亡过程中的关键参与者，并已被发现有助于多种疾病的发病机制，包括缺血性中风等神经系统疾病。本研究旨在研究急性缺血性卒中（AIS）患者和无缺血性事件的对照组患者血清Caspase-3水平。此外，我们探讨了与AIS临床结局的潜在关联.在CT扫描阴性的情况下，我们招募了69例具有AIS临床体征和症状的连续患者，这些患者在症状发作的前24小时内在Galati急诊临床医院的临床神经科就诊。对照组包括68例无脑缺血病变的患者。两组的比较显示，入院后24和48h的caspase-3水平显着升高。caspase-3水平与AIS的临床特征之间没有显着关联。然而,在对中度/重度和重度中风患者进行的亚组分析中，caspase-3水平降低与早期死亡率相关.当考虑所有AIS患者时，Caspase-3水平与AIS严重程度或预后没有直接相关。美国国立卫生研究院中重度卒中量表（NIHSS）评分，caspase-3可能是早期死亡的预后指标。需要进一步的研究来证实这些结果，并进一步探索这些发现背后的机制。
